Exact Sciences (EXAS) PT Raised to $102 at Baird

Baird analyst Catherine Ramsey Schulte raised the price target on Exact Sciences (NASDAQ: EXAS) to $102.00 while maintaining a Outperform rating.

They also raised estimates for 2019 revenue and completed tests, given the 4Q beat. They now model 1.50M completed tests (prior: 1.44M) and $730.0M in revenue (prior: $702.5M). This includes sequential test increases of 22.2K in 1Q, 49.5K in 2Q, 33.9K in 3Q, and 29.3K in 4Q (prior: +23.8K, +52.2K, +43.9K, +31.2K, respectively).

"We continue to see the potential for upside even vs. our raised estimates, and EXAS remains one of our top ideas," the analyst adds.

You May Also Be Interested In

• Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
• Revolution (RVMD) PT Raised to $179 at Bernstein SocGen Group
• Idex Corp. (IEX) Reiterated at Buy by Stifel